Chat with an Expert

StemSpan™ T Cell Generation Kit

For expansion and differentiation of human CD34+ hematopoietic progenitor cells to T cells

More Views

StemSpan™ T Cell Generation Kit

For expansion and differentiation of human CD34+ hematopoietic progenitor cells to T cells

1 Kit
Catalog #09940
1,121 USD

StemSpan™ SFEM II

Serum-free medium for culture and expansion of hematopoietic cells

100 mL
Catalog #09605
123 USD

StemSpan™ Lymphoid Progenitor Expansion Supplement (10X)

Supplement for the expansion and differentiation of lymphoid progenitor cells

5 mL
Catalog #09915
249 USD

StemSpan™ Lymphoid Differentiation Coating Material (100X)

Coating material for the differentiation of lymphoid cells

0.25 mL
Catalog #09925
193 USD

StemSpan™ T Cell Progenitor Maturation Supplement (10X)

Supplement for the maturation of T cell progenitors to T cells

12.5 mL
Catalog #09930
249 USD

Overview

StemSpan™ T Cell Generation Kit has been developed to differentiate CD34+ cells isolated from cord blood (CB) to T cells, without use of stromal cells. This kit typically promotes the expansion of thousands of CD3+TCRαβ+ T cells in cultures initiated with CD34+ human CB cells. At 6 weeks, the majority of these cells are CD4+CD8+ double-positive (DP) cells, and can mature to CD8+ single-positive (CD8 SP) T cells after an additional week of stimulation.

StemSpan™ Lymphoid Progenitor Expansion Supplement (10X) contains a combination of recombinant human cytokines and other additives formulated to selectively promote the expansion and differentiation of CD34+ cells isolated from human CB samples to CD7+CD5+ progenitor T (pro-T) cells. Additionally, StemSpan™ T Cell Progenitor Maturation Supplement (10X) enables further maturation of pro-T cells to DP cells. It also supports maturation of DP cells to CD8 SP T cells with additional stimuli. StemSpan™ Lymphoid Progenitor Expansion Supplement (10X) and StemSpan™ T Cell Progenitor Maturation Supplement (10X) are intended for use in combination with StemSpan™ SFEM II medium, and on plates coated with StemSpan™ Lymphoid Differentiation Coating Material (100X).
Components:
• StemSpan™ SFEM II, 2 x 100 mL
• StemSpan™ Lymphoid Progenitor Expansion Supplement (10X), 5 mL
• StemSpan™ Lymphoid Differentiation Coating Material (100X), 2 x 0.25 mL
• StemSpan™ T Cell Progenitor Maturation Supplement (10X), 12.5 mL
Subtype:
Supplements; Specialized Media
Cell Type:
Hematopoietic Stem and Progenitor Cells; T Cells
Species:
Human
Application:
Expansion; Differentiation; Cell Culture
Brand:
StemSpan
Area of Interest:
Immunology; Cancer Research; Stem Cell Biology; T Cell Engineering
Formulation:
Serum-Free

Scientific Resources

Educational Materials

(4)

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications

Data

Figure 1. Frequency and Yield of CD7+CD5+ Pro-T Cells After 14 Days of Culture

CB-derived CD34+ cells (freshly isolated or frozen) were cultured for 14 days in StemSpan™ SFEM II containing Lymphoid Progenitor Expansion Supplement (Catalog #09915) on plates coated with Lymphoid Differentiation Coating Material (Catalog #09925). Cells were harvested and analyzed for CD7 and CD5 expression by (A) flow cytometry. The (B) average frequency of viable CD7+CD5+ pro-T cells on day 14 was 70%, with ~200 CD7+CD5+ cells produced per input CD34+ cell. Shown are means with 95% confidence intervals (n = 33).

Figure 2. Frequency and Yield of CD4 ISP and CD4+CD8+ DP Cells After 42 Days of Culture

CB-derived CD34+ cells (freshly isolated or frozen) were cultured with the StemSpan™ T Cell Generation Kit (Catalog #09940) for 42 days and (A) analysed by flow cytometry for the expression of CD4, CD8, CD3 and TCRαβ. The (B) frequency and (C) yield of CD4 ISP, double-positive (CD4+CD8+) and CD3+TCRαβ+-expressing double-positive cells (CD4+CD8+CD3+TCRαβ+) are shown. On average, 38% of the total viable population were DP (CD4+CD8+), of which 35% co-expressed CD3 and TCRαβ. The yields of total DP cells and CD3+TCRαβ+ DP cells per input CD34+ cell were ~23,000 and ~9,000, respectively. Shown are means with 95% confidence intervals (n = 31).

Figure 3. Frequency and Yield of CD8 SP T Cells After 49 Days of Culture

DP cells were further matured into CD8 SP T cells by culturing for an additional 7 days in StemSpan™ SFEM II with T Cell Progenitor Maturation Supplement (Catalog #09930), IL-15 (Catalog #78031) and ImmunoCult™ CD3/CD28/CD2 T Cell Activator (Catalog #10970) on coated plates. On day 49, cells were (A) analyzed by flow cytometry for the expression of CD3, TCRαβ, CD4 and CD8. The (B) frequency and yield of CD3+TCRαβ+-expressing cells and their subsets are shown. On average, 54% of the CD3+TCRαβ+ cells were DP (CD4+CD8+) and 38% were CD8 SP (CD4-CD8+). The average yield of CD8 SP T cells per input CD34+ cell was ~6,000. CD3+TCRαβ+ CD4 SP (CD4+CD8-) T cells were detected at very low frequencies (data not shown). Shown are means with 95% confidence intervals (n = 12).

STEMCELL TECHNOLOGIES INC.’S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.